Table 1.
Baseline characteristics at first-ever stroke of N = 1701 participants, total sample and stratified per epoch.
| Baseline characteristics of study population, total and per epoch | ||||
|---|---|---|---|---|
| Totala (N = 1701) | Epoch 1 (N = 529) | Epoch 2 (N = 674) | Epoch 3 (N = 498) | |
| Categorical characteristic | n (%) | |||
| Sex, female | 1017 (59.8) | 311 (58.8) | 417 (61.9) | 289 (58.0) |
| Cohort | ||||
| RS-I | 1285 (75.5) | 529 (100) | 507 (75.2) | 249 (50.0) |
| RS-II | 295 (17.3) | 0 (0) | 143 (21.2) | 152 (30.5) |
| RS-III | 121 (7.1) | 0 (0) | 24 (3.6) | 97 (19.5) |
| Ancestry | ||||
| Caucasian | 1362 (80.2) | 398 (75.2) | 562 (83.4) | 402 (80.7) |
| Non-Caucasian | 18 (1.1) | 2 (0.4) | 7 (1.0) | 9 (1.8) |
| Stroke type, first event | ||||
| Haemorrhagic | 141 (8.3) | 25 (4.7) | 64 (9.4) | 52 (10.4) |
| Unspecified | 449 (26.4) | 210 (39.9) | 180 (26.7) | 59 (11.8) |
| Ischaemic | 1111 (65.3) | 294 (55.6) | 430 (63.8) | 387 (77.7) |
| Large-artery atherosclerosis | 87 (7.8) | 27 (9.2) | 28 (6.5) | 32 (8.3) |
| Cardioembolism | 216 (19.4) | 45 (15.3) | 88 (20.5) | 83 (21.4) |
| Small-vessel occlusion | 80 (7.2) | 40 (13.6) | 28 (6.5) | 12 (3.1) |
| Stroke of other determined etiology | 28 (2.5) | 9 (3.1) | 14 (3.3) | 5 (1.3) |
| Stroke of undetermined etiology | 700 (63.0) | 173 (58.8) | 272 (63.3) | 255 (65.9) |
| Stroke type, second event | 331 (19.5) | 130 (39.3) | 146 (44.1) | 55 (16.6) |
| Haemorrhagic | 34 (10.3) | 15 (11.5) | 12 (8.2) | 7 (12.7) |
| Unspecified | 119 (36.0) | 63 (48.6) | 47 (32.2) | 9 (16.4) |
| Ischaemic | 178 (53.8) | 52 (40.0) | 87 (59.6) | 39 (70.9) |
| Large-artery atherosclerosis | 13 (7.3) | 3 (5.8) | 7 (8.0) | 3 (7.7) |
| Cardioembolism | 42 (23.6) | 15 (28.8) | 16 (18.4) | 11 (28.2) |
| Small-vessel occlusion | 10 (5.6) | 7 (13.5) | 3 (3.4) | 0 (0) |
| Stroke of other determined etiology | 2 (1.1) | 1 (1.9) | 1 (1.1) | 0 (0) |
| Stroke of undetermined etiology | 111 (62.4) | 26 (50.0) | 60 (69.0) | 25 (64.1) |
| Medication use prior to first stroke | ||||
| Diabetes medication | 156 (9.2) | 30 (5.7) | 69 (10.2) | 11.4 (11.4) |
| Anti-hypertensives | 818 (48.1) | 214 (40.5) | 320 (47.5) | 284 (57.0) |
| Statins & other lipid control | 218 (12.8) | 9 (1.7) | 69 (10.2) | 140 (28.1) |
| Anti-thrombotic agents | 446 (26.2) | 32 (6.6) | 230 (34.1) | 181 (36.3) |
| Smoking prior to first stroke | ||||
| Never | 410 (24.1) | 106 (20.0) | 179 (26.6) | 125 (25.1) |
| Past | 618 (36.3) | 125 (23.6) | 254 (37.7) | 239 (48.0) |
| Current | 417 (24.5) | 165 (31.2) | 173 (25.7) | 79 (15.9) |
| Continuous, normally distributed, characteristic | Mean (SD) | |||
| Age at first event, years | 80.3 (9.0) | 79.7 (8.8) | 80.3 (9.2) | 80.9 (8.9) |
| Continuous, not-normally distributed, characteristic | Median (IQR) | |||
| Time between first-ever and first recurrent stroke, years | 1.8 (0.5–4.6) | 2.5 (0.8–6.0) | 1.5 (0.4–3.6) | 1.5 (0.5–3.6) |
| Time between last control visit and first-ever stroke, years | 2.9 (1.4–4.9) | 1.6 (0.9–3.0) | 3.5 (1.9–5.2) | 3.9 (2.2–7.0) |
Data and percentages represent original values including missing data.
a
Missing values were present for ancestry (18.9%), diabetes medication (24.3%), anti-hypertensive (7.0%), statins & other lipid control (24.3%), anti-thrombotic agents (24.3%) and smoking status (15.0%).